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Background: Human immunodeficiency virus type 1(HIV-1) infects and activates innate immune cells in the brain
resulting in inflammation and neuronal death with accompanying neurological deficits. Induction of inflammasomes
causes cleavage and release of IL-1β and IL-18, representing pathogenic processes that underlie inflammatory diseases
although their contribution HIV-associated brain disease is unknown.
Results: Investigation of inflammasome-associated genes revealed that IL-1β, IL-18 and caspase-1 were induced in
brains of HIV-infected persons and detected in brain microglial cells. HIV-1 infection induced pro-IL-1β in human
microglia at 4 hr post-infection with peak IL-1β release at 24 hr, which was accompanied by intracellular ASC
translocation and caspase-1 activation. HIV-dependent release of IL-1β from a human macrophage cell line, THP-1, was
inhibited by NLRP3 deficiency and high extracellular [K+]. Exposure of microglia to HIV-1 gp120 caused IL-1β production
and similarly, HIV-1 envelope pseudotyped viral particles induced IL-1β release, unlike VSV-G pseudotyped particles.
Infection of cultured feline macrophages by the related lentivirus, feline immunodeficiency virus (FIV), also resulted in
the prompt induction of IL-1β. In vivo FIV infection activated multiple inflammasome-associated genes in microglia,
which was accompanied by neuronal loss in cerebral cortex and neurological deficits. Multivariate analyses of data
from FIV-infected and uninfected animals disclosed that IL-1β, NLRP3 and caspase-1 expression in cerebral cortex
represented key molecular determinants of neurological deficits.
Conclusions: NLRP3 inflammasome activation was an early and integral aspect of lentivirus infection of microglia,
which was associated with lentivirus-induced brain disease. Inflammasome activation in the brain might represent a
potential target for therapeutic interventions in HIV/AIDS.
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Despite the success of antiretroviral therapies (ART), hu-
man immunodeficiency virus type 1 (HIV-1) infection
remains a major global health challenge for which the
pathogenic mechanisms resulting in the acquired im-
munodeficiency syndrome (AIDS) and its associated
complications remain incompletely understood. HIV-1
enters the central nervous system (CNS) during primary
infection and productively infects brain macrophage cell
types including microglia and infiltrating macrophages
[1]. Indeed, all of the immunosuppressive lentiviruses,
including human (HIV), simian (SIV), bovine (BIV) and* Correspondence: chris.power@ualberta.ca
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unless otherwise stated.feline (FIV) immunodeficiency viruses, share the prop-
erty of efficiently infecting both macrophage and lymph-
oid cells. This shared cell tropism contributes to chronic
immune disease and eventual CNS disease during infec-
tion by each of these viruses, as evidenced by neuronal
injury and neurological disabilities (motor/gait impair-
ments, memory deficiencies, executive/behavioral abnor-
malities) [2]. However, the primary pathogenic event(s)
underlying neuronal injury and death during lentivirus
infections remain uncertain. CNS-associated disease rep-
resents a substantial burden among HIV-1 infected indi-
viduals because of the brain’s privileged immune status
together with limited accessibility of antiretroviral ther-
apies [3]. The prevalence of HIV-associated neurocogni-
tive disorders is reported to be approximately 20-50%
among treated populations [4,5]. The development oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion involving the induction of cytokines, chemokines,
proteases and free radicals with ensuing neuronal injury
and death [1,3,6].
Inflammation within the brain is a highly orchestrated
response by the immune system to infections or non-
infectious disorders. There is a burgeoning growth in in-
formation regarding the composition and functions of
the brain’s innate immune system, largely implicating
microglia, trafficking macrophages, and astrocytes [7-9].
Cells of the innate immune system express pattern rec-
ognition receptors (PRRs), which recognize molecular
patterns on infectious agents or disease-associated host
molecules. As part of an inflammatory response, some
cytosolic PRRs are capable of forming complexes termed
‘inflammasomes’, which direct the activation of caspase-1
through auto-proteolysis leading to the cleavage and
subsequent release of IL-1β and IL-18 [10]. Inflamma-
some activation has been implicated in multiple infec-
tious and immune diseases including those involving the
brain [11-14]. The brain is sensitive to IL-1β and IL-18
signalling at both a systemic and local level because mul-
tiple cell types in the CNS express the receptors for
these cytokines [15,16].
The innate immune response to HIV-1 is attenuated
in some macrophage cell types through the actions of
host molecules such as TREX1 or SAMDH1, which pre-
vent sufficient accumulation of viral PAMPs within the
cytosol to trigger a response [17,18]. Thus, many innate
immune cell types exhibit restricted responses to HIV-1
infection. An exception is the plasmacytoid dendritic cell
(pDC), which senses viral RNA through TLR7 and re-
leases type 1 interferons [19-21]. Importantly, this is part
of an immediate response to virus and does not require
the establishment of productive infection [19,20]. Al-
though the stimulatory capacity of free virus is much
less than that of HIV-1 infected cells, both responses re-
quire uptake of virus into endosomes and in the context
of free virus, uptake occurs independent of membrane
fusion mediated viral entry [19-21].
IL-1β expression is elevated in the CNS during HIV-1,
SIV and FIV infections [22-24]. Additionally, IL-1β has
been reported to be released from monocyte-derived
macrophages or from mixed glial cultures (human or
rat) in response to live virus or soluble HIV-1 proteins
[25-28]. Recent studies have also linked polymorphisms
in the inflammasome gene NLRP3 to an increased sus-
ceptibility to HIV-1 infection [29,30] and HIV-1 has
been implicated in priming the NLRP3 inflammasome in
macrophages [31]. Although these observations imply
the formation of an inflammasome complex in response
to HIV-1, this complex has not been explicitly examined
in previous studies, particularly in the context of end-
organ disease. These findings prompted us to hypothesizethat expression and functions of inflammasome compo-
nents contributed to the inflammatory response of CNS
cells to HIV-1 and to the development of lentivirus-
induced neurological disease.
Herein, we report on the expression of individual
inflammasome components in the brains of patients with
HIV/AIDS, chiefly in microglia, which was verified in cul-
tured primary human microglia. In addition, exposure of
primary human microglia or PMA-differentiated THP-1
cells to HIV-1 led to a rapid and short-lived release of IL-
1β that was dependent on caspase-1 activation, K+ efflux
and the NLRP3 inflammasome. Furthermore, the expres-
sion and predominance of inflammasome components
and the participation of IL-1β in neuropathogenesis was
confirmed using an in vivo model of lentivirus (FIV)-
induced immunodeficiency and neurological disease.
Results
Inflammasome substrates and components are expressed
in the brain during HIV-1 infection
Previous reports have highlighted increased IL-1β expres-
sion in the brains of HIV-infected persons [22]. To extend
these studies, the expression of IL-1B and IL-18 in con-
junction with the inflammasome-forming nucleotide-
binding oligomerization domain-like receptors (NLRs),
NLRP1 and NLRP3, as well as inflammasome components
caspase-1 and apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC) was ex-
amined in the cerebral white matter from HIV-infected
(HIV [+]) and uninfected (HIV [−]) persons (Figure 1A).
There was increased expression of caspase-1 (CASP1) and
the inflammasome substrates, IL-1β and IL-18, in the
brains of the HIV [+] group (p < 0.05) while the transcript
expression of NLRP1, NLRP3 or ASC was similar across
groups (Figure 1A). To verify protein expression of
inflammasome components, immunohistochemistry was
performed on cerebral white matter sections from HIV
[−] and HIV [+] persons, revealing minimal MHC Class II
immunolabelling in sections from HIV [−] persons, while
there was a marked increase in cells staining immunoposi-
tive for MHC Class II in the HIV [+] sections (Figure 1B).
IL-1β immunoreactivity was not evident in HIV [−] brain
sections but was detected in white matter from HIV [+]
persons, with co-localization in MHC Class II immunopo-
sitive cells (Figure 1B, inset i) and in cells with activated
microglial/macrophage morphology (Figure 1B, inset ii).
Similarly, IL-18 immunoreactivity was negligible in HIV
[−] white matter but detected within the white matter of
HIV [+] persons (Figure 1B, inset iii). ASC immunoreac-
tivity was observed in both groups, likely reflecting the
constitutive nature of this protein (Figure 1B, inset iv).
Thus, several components of the inflammasome exhibited
increased expression in the brain during HIV-1 infection,















































Figure 1 Expression of inflammasome components and
substrates in the HIV-1 infected human brain. A. Relative fold
change (RFC) in mRNA expression in the white matter of persons
with HIV-1 infection (HIV [+]) (n = 12) compared to other disease
controls (HIV [−]) (n = 12), as measured by semi-quantitative real-
time PCR. Mean values are reported. Bars indicate standard error.
*indicate p-value of <0.05. B. Immunohistochemistry staining of
cerebral white matter sections from other disease control (HIV [−])
and HIV-infected (HIV [+]) (200X view). Inset ‘i’ represents double
immunostaining for MHC II and IL-1β. Insets ‘ii’, ‘iii’ and ‘iv’ are
magnified images of the indicated cells within the HIV [+] section.
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human primary CNS cell types
Although different components of inflammasome ma-
chinery have been reported in the human brain, their
specific cellular expression was uncertain. Using isolated
primary human neural cells including Iba-1 immunopo-
sitive microglia (Figure 2A), GFAP immunopositive as-
trocytes (Figure 2B) and MAP-2 immunopositive neurons
(Figure 2C), the mRNA expression of CASP1, NLRP1,
NLRP3, NLRC4 and AIM2 was investigated in each cell
type (Figure 2D). The purity of these primary cell cultures
has been previously characterized by both our group as
well as others [32-38]. Isolated microglia exhibited the
highest expression of all the genes examined, while ex-
pression in astrocytes or neurons was either much lower
or not detected (Figure 2D). In addition, a similar com-
parison of gene expression between primary microglia and
astrocytes, by semi-quantitative real-time PCR confirmed
these observations (Figure 2E). Of note, the expression of
inflammasome components in primary human microglia
and astrocytes was also compared with that of the human
monocyte cell line, THP-1, revealing gene expression
levels for THP-1 cells and primary microglia that were
broadly similar while the expression of inflammasome-
related genes in astrocytes was markedly less (Additional
file 1: Figure S1).
Although gene expression studies suggested that,
among the human CNS cells examined, microglia are
best equipped with inflammasome components, astro-
cytes have been reported to express and/or release IL-1β
upon activation by various stimuli including bacterial
lipopolysaccharide (LPS) [39-41]. To compare the ability
of primary human microglia and astrocytes to express
IL-1β protein, human microglia and astrocytes were ex-
posed to LPS. This stimulus induced robust IL-1β ex-
pression in microglia as evidenced by immunodetection
of the pro-form of the cytokine (~31 kD) (Figure 2F). In
addition, full-length caspase-1 (~45 kD) was constitu-
tively expressed in microglia. However, neither IL-1β nor
caspase-1 were detected in primary astrocytes even
under conditions of LPS exposure (Figure 2F), implying
that astrocytes are unlikely to be a major contributor to
















































































Figure 2 Expression and activation of the inflammasome in primary human CNS cells. Isolated primary human cells including microglia (A),
astrocytes (B) and neurons (C) were immunolabelled with antibodies to Iba-1, GFAP and MAP-2, respectively, to verify the purity of cell cultures.
D. Qualitative RT-PCR showing transcript expression of caspase-1 as well as various inflammasome-forming cytoplasmic pattern recognition
receptors in primary cultured human microglia, astrocytes and neurons. E. Semi-quantitative real-time PCR showing the relative fold change in
inflammasome-associated gene expression in cultured primary human microglia and astrocytes. Bars indicate standard error. F. Protein expression
of IL-1β and caspase-1 in primary human microglia but not astrocytes. G. IL-1β release from Mock-or LPS-primed (10 ng/mL, 6 hr) primary human
microglia followed by ATP stimulation (5 mM, 1 hr). Mean values are reported. Bars indicate standard error.
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the first purported step (“Signal 1”) required for ex-
pression of the IL-1β pro-form. A second signal (“Signal
2”) is also required to trigger the formation of the inflam-
masome complex, which mediates the maturation and re-
lease of IL-1β from cells [42]. To confirm that human
microglia would respond in a similar manner, cultures
were primed with LPS (Signal 1) followed by stimula-
tion with extracellular ATP (Signal 2), which is anestablished activator of the NLRP3 inflammasome.
While LPS exposure alone did not induce release of IL-
1β, subsequent ATP (5 mM) treatment triggered release
of the cytokine, pointing to a conventional response
of human microglia to NLRP3 activating paradigms
(Figure 2G). These studies established that microglia
were the chief sources of IL-1β in the human brain and
were also the principal cells encoding components of
the inflammasome.
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following HIV-1 infection
As several inflammasome components were induced in the
brain during HIV-1 infection, the ability of HIV-1 to acti-
vate inflammasome-dependent IL-1β release was explored
using primary human microglial cultures. Following infec-
tion of cultured microglia with the CCR5-dependent
HIV-1 strain, HIV-1SF162, there was an observed release of
HIV-1 p24 detected at day 4 post-infection, which in-
creased at days 7 and 10 (Figure 3A). In contrast, IL-1β
release from the same HIV-infected cells was highest
at day 4 post-infection but declined at days 7 and 10
(Figure 3B). In addition, pre-treatment of cells with
reverse-transcriptase inhibitors zidovudine (AZT) or efavir-
enz failed to block HIV-mediated expression of IL-1β in
microglia (Additional file 1: Figure S1B). This observation
suggested that very early HIV-1 exposure or infection pro-
moted IL-1β release from cells; thus, the immediate re-
sponse of microglia to HIV-1SF162 exposure was examined.
Analyses of IL-1β expression in microglia following expos-
ure to HIV-1SF162 showed induction of full length IL-1β
(p31) by 4 hr post-infection increasing by 24 hr post-
infection at which time the processing of IL-1β could be
observed in the appearance of a 29 kD band, representing
the first of two cleavage events that are required for the
maturation of the cytokine [43,44] (Figure 3C). In addition,
IL-1β release from HIV-1SF162-exposed microglia was evi-
dent at time points as early as 6 hours (Figure 3D).
Caspase-1 expression was stable during HIV-1SF162 expos-
ure (Figure 3C) although as is often reported it was not
possible to observe processed caspase-1 in the cell lysates
[45]. However, blocking caspase activity by applying the
caspase inhibitor YVAD-fmk, prior to exposure with HIV-
1SF162, inhibited both the processing (Figure 3E) and re-
lease (p < 0.05) (Figure 3F) of IL-1β from human microglia.
In addition, an inhibitor of actin polymerization, cytochala-
sin D, also inhibited IL-1β release from human microglia,
suggesting that virus might be sensed through an endocytic
pathway (Additional file 1: Figure S1C). As soluble HIV-1
gp120 has been previously reported to induce IL-1β release
from macrophage cells or glial cultures [25,27,28], this re-
sponse was investigated in primary human microglia in the
presence of YVAD-fmk; exposure of human microglia to
soluble gp120 encoded by the CCR5-dependent HIV-1
CM235 strain, induced IL-1β expression (Figure 3G) and
release (Figure 3H), which was significantly inhibited by
YVAD-fmk.
IL-1β release in response to HIV-1 is dependent on the
NLRP3 inflammasome
The above studies suggested that exposure of microglia to
HIV-1 rapidly led to inflammasome-dependent cleavage
and release of IL-1β. To pursue this observation further,
the effects of HIV-1 on the human monocytic cell line,THP-1, were examined. Although PMA-differentiated
THP-1 cells are not productively infected by HIV-1 due to
high expression of SAMDH1, these cells remain permis-
sive to viral infection [46]. Exposure of differentiated
THP-1 cells to HIV-1SF162 but not the X4-dependent
virus, HIV-1NL4–3, (Additional file 1: Figure S1D) for 4 hr
induced expression of IL-1β, which was also processed to
its mature form (Figure 4A) and released (Figure 4B) from
cells. Furthermore, this response was inhibited by the
addition of high extracellular K+ (p < 0.01), which prevents
the K+ efflux required for activation of NLRP3 or by
addition of the caspase inhibitor YVAD-fmk (p < 0.01)
(Figure 4C). Importantly, the response could not be inhib-
ited by the presence of the fusion inhibitor, enfuviride
(T20), or the CCR5 antagonist, maraviroc (Figure 4D). Be-
cause the inhibitory effect of high extracellular K+ sug-
gested that the NLRP3 inflammasome may be involved
in the response to HIV-1, the requirement for NLRP3
in inflammasome induction by HIV-1 was subsequently
tested by comparing the response of THP-1 cells with a
THP-1 derived cell line that was deficient in NLRP3,
THP1-defNLRP3. NLRP3 deficiency in THP1-defNLRP3
cells was confirmed by RT-PCR (Additional file 2: Figure
S2). Although both THP-1 and THP1-defNLRP3 cells ex-
hibited robust responses to the AIM2 inflammasome lig-
and, poly dA:dT, the response to HIV-1 was significantly
reduced in the THP1-defNLRP3 cells compared with wild
type THP-1 cells, supporting the notion that the NLRP3
inflammasome was integral in HIV-mediated activation
and release of IL-1β (Figure 4E). Because primary micro-
glia also responded to recombinant viral envelope protein
gp120, we sought to compare the responses of THP-1
cells to pseudotyped viral particles produced through the
co-transfection of HxBRuR+E− (which lacks functional en-
velope gene) with either VSV-G or the HIV-1 envelope
(HIV-1Env3098). Exposure of differentiated THP-1 cells to
HxBRuR+E− pseudotyped particles carrying HIV-1Env3098
induced a strong IL-1β release while cells exposed to
HxBRuR+E− carrying the VSV-G exhibited no detectable
response (Figure 4F), thus confirming the importance of
the HIV-1 envelope in IL-1β induction.
HIV-1 infection induces ASC translocation in microglia
ASC represents an important protein in the formation of
inflammasomes, translocating to the cytoplasm to facilitate
inflammasome aggregation. To determine if ASC trans-
location was involved in inflammasome formation dur-
ing HIV-1 infection, we investigated its expression before
and during HIV-1SF162 infection of human microglia.
These studies revealed that ASC immunoreactivity was
not detected in the cytoplasm of mock-infected microglia
(Figure 5A). In contrast, ASC immunoreactivity was
discernible at 1 hr post-infection (Figure 5B) and increased
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Figure 3 (See legend on next page.)
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Figure 3 IL-1β expression and release from primary human microglia following HIV-1 infection or exposure. A. Viral p24 and B. IL-1β
release from microglia at days 4, 7 and 10 following infection with HIV-1SF162.C. IL-1β induction and D. release from microglia cultures over 24 hr
following exposure to HIV-1SF162. E. Induction, processing and F. release of IL-1β following 24 hr exposure to HIV-1SF162 +/− the caspase inhibitor
YVAD-fmk (80 μM). G. Induction and H. release of IL-1β from microglia cultures exposed to recombinant gp120 (80 nM) for 24 hr +/− YVAD-fmk.
Mean levels are reported for each ELISA. Bars indicate standard error. We compared the effect of HIV-1gp120 exposure on IL-1β release +/−
YVAD-fmk using two-tailed Student t-test (*p < 0.05).
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appearance (Figure 5D). These findings underscored
the activation of ASC during HIV-1 infection and pro-

































































Figure 4 IL-1β release in response to HIV-1SF162 exposure is depende
A. Induction, processing and B. release of IL-1β from PMA-differentiated TH
PMA-differentiated THP-1 cells exposed to HIV-1SF162 for 4 hr +/− extrace
PMA-differentiated THP-1 cells following 18 hr exposure to HIV-1SF162 +/−
maraviroc (100nM). E. IL-1β release from PMA-differentiated THP-1 cells o
(poly dA:dT was transfected using Lipofectamine 2000). F. IL-1β release fr
VSVG, or HxBRuR+E− + HIV-1Env3098 for 24 hours. Mean levels are reported
indicates that IL-1β was “Not Detected”.HIV-1 infection activates caspase-1 in microglia
Caspase-1 activation is a signature aspect of inflamma-
some assembly and action. We examined caspase-1 ac-
tivity in mock- and HIV-1SF162-infected microglia at
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P-1 cells following 4 hr exposure to HIV-1SF162. C. IL-1β release from
llular KCl (50 mM) or YVAD-fmk (80 μM). D. Release of IL-1β from
the inhibitor of viral fusion T20 (20 μg/mL) or the CCR5 antagonist
r THP1-defNLRP3 cells exposed to HIV-1SF162 or poly dA:dT for 4 hr
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Figure 5 HIV-1SF162 infection of human microglia induces rapid ASC intracellular translocation. A. Mock-infected microglia exhibit minimal
ASC immunoreactivity. B. At 1 hr post-infection ASC immunoreactivity (red) was detected in the cytoplasm. C. At 2 hr post-infection, punctate
ASC immunoreactivity was evident in the cytoplasm of microglia. D. At 3 hr post-infection, aggregates of ASC immunoreactivity was readily
apparent in microglia. (Original magnification 400X).
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stained nuclei) (Figure 6A) but HIV-infected microglia
exhibited abundant caspase-1 activity (Figure 6B). Quan-
titative analyses of caspase-1 activity in mock- and HIV-
infected microglia at 4 and 24 hr post-infection showed
significant increases in caspase-1 activity in HIV-infected
microglia at both time points (Figure 6C). These results
further verified inflammasome activation in human micro-
glia following HIV-1 infection.
IL-1β induction in activated microglia is associated with
neurobehavioral deficits in FIV infection
The above clinical and in vitro observations pointed to a
role for inflammasome-dependent IL-1β expression and
release from microglia during HIV-1 infection. To exam-
ine the relevance of these observations in an established
in vivo model of AIDS-associated neurologic disease,
microglial activation, IL-1β expression, and expression
of inflammasome components were examined in cats
infected with a neurovirulent FIV strain, FIV-Ch. To
confirm the direct effect of viral exposure on IL-1β ex-
pression, feline monocyte-derived macrophages were in-
fected with FIV-Ch, showing that FIV induced IL-1β
expression within 8 hr, as was observed for microgliaand THP-1 cells exposed to HIV-1 (Figure 7A). In vivo
expression was examined, revealing that in mock-
infected (FIV [−]) animals, Iba-1 immunopositive micro-
glia were observed in both striatum and cortex but the
number and size (hypertrophied) of Iba-1 immunoposi-
tive microglia was increased in the FIV-infected (FIV
[+]) animals (Figure 7D, row 1). IL-1β immunoreactivity
was minimal in the FIV [−] striatum and cortex but was
readily detected in both regions in the FIV [+] animals
(Figure 7D, row 2). In fact, IL-1β immunopositive micro-
glial nodules were evident in the FIV [+] brains (Figure 7D,
inset i), which were co-localized with Iba-1 immunoreac-
tivity (Figure 7D, inset ii). Caspase-1 immunolabeling was
also present in the FIV [−] brains within cells resembling
microglia (Figure 7D, row 3) but was increased on
hypertrophied cells in brains from FIV [+] animals.
Nissl staining of FIV [−] cortex showed numerous neu-
rons (Figure 7D, row 3) although neuronal density was
diminished in the FIV [+] brains. Neuronal counting
showed that cortical neuronal density was reduced in
the FIV [+] group (Figure 7C). Mean blood CD4+ T cell
levels were significantly suppressed in FIV [+] animals
at weeks 8 and 12 post-infection compared to FIV [−]


















Figure 6 HIV-1SF162 infection of human microglia activates
caspase-1. A. Caspase-1 activity was not detected in mock-infected
microglial cultures that were labeled with Hoescht nuclear stain.
B. In contrast, microglia infected by HIV-1 showed caspase-1 activity
at 24 hr post-infection (Original magnification 400X). C. Quantitation
of caspase-1 activity in microglia at 4 and 24 hr post-infection
showed an increased in caspase-1 activity induced by HIV-1 infection
and also over time. (Mean values reported. Bars indicate standard
error. Student t-test, *p < 0.05).
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post-infection (p < 0.01) (Additional file 3: Figure S3A). In
addition, viral pol RNA copy numbers were similar in the
striatum and cortex of the FIV [+] animals but were not de-
tected in the FIV [−] animals (Figure 7E). Neurobehavioral
studies in FIV [−] and FIV [+] animals revealed that mean
Gait Variance, an indicator of gait ataxia, was increased
in the FIV [+] animals (p < 0.01) (Figure 7F), together with
a reduction in mean performance in the Object Memory
Test (OMT) (p < 0.001) (Figure 7G) compared to the FIV
[−] group. Similarly, the FIV [+] group performed slower
(p < 0.05) and with more errors (p < 0.01) on the Maze
Tasks (Additional file 3: Figure S3B and S3C). These data
indicated that microgliosis accompanied by induction of
IL-1β in microglia was associated with immunosuppression
and neurobehavioral deficits in this HIV/AIDS model.
Molecular indicators of neurovirulence in FIV-infected animals
To examine the in vivo relationship between inflamma-
some expression and FIV infection, several inflamma-
some–associated genes were examined in brains fromthe FIV [−] and FIV [+] groups (Figure 8A). Mean IL1B,
but not IL18, transcript levels were increased in the cor-
tex of the FIV [+] group compared to the FIV [−] group
(p < 0.01). CASP1 transcript levels exhibited a trend to-
ward increased expression in brains from FIV [+] ani-
mals while NLRP3 transcript levels were increased in the
cortex of FIV [+] animals (p < 0.05). Brain ASC transcript
levels were similar among the FIV [−] and FIV [+]
groups while TNFA transcript levels were increased in
the striatum of FIV [+] animals (p < 0.05).
To determine the multivariate sources of variance
within this in vivo model, principal component analyses
(PCA) were performed, using 49 clinical, neurobehavioral,
and molecular (cerebral cortex and striatum) variables
measured in FIV [−] and FIV [+] animals, including
the expression of other immune genes in the brain
(Additional file 4: Figure S4 and Additional file 5: Figure
S5). The first principal component (PC1) contributed
32.9% to the total variance, and therein clearly separated
the FIV [−] from the FIV [+] animals (Figure 8B). The
second principal component (PC2) contributed an add-
itional 15% to total variance that was orthogonal to PC1,
and identified intra-group variance. Additionally, univari-
ate Spearman rank correlation analyses was performed
(Additional file 5: Figure S5A). To investigate multivariate
similarities between variables and animals, agglomerative
Hierarchical Cluster Analysis (HCA) was performed. Only
variables that contributed to the first PC of the PCA ana-
lysis were included in the HCA analysis as this component
uniquely contributed to the separation of the two clinical
groups. Thirty-two variables were identified as signifi-
cantly contributing to PC1 using bootstrap re-sampling
(Additional file 5: Figure S5B). The HCA is presented as a
heat map with associated dendrograms (Figure 8C), re-
vealing that multiple variables were implicated in distin-
guishing the FIV [−] from FIV [+] groups. The HCA
heatmap showed FIV [−] and FIV [+] animals grouped
into two distinct clusters, mirroring the results of the
PCA analysis. Similarly, the observed variables also
grouped into two distinct clusters: those positively corre-
lated with FIV [+] and those positively correlated with FIV
[−]. Within the set of variables positively correlated with
the FIV [+] animals there were several sub-clusters reflect-
ing minor heterogeneity in disease outcome. Within the
context of this model, the expression of CASP1 and
NLRP3 were highly correlated with each other both in the
cortex and striatum. Cortical expression of these genes
showed strong correlation to another sub-cluster of vari-
ables that included cortical IL10, striatal CD8B, F4/80,
and maze errors. The next highest degree of correlation
to these six variables was cortical IL1B expression. The
cluster of variables that were positively correlated with
FIV [−] animals included blood CD4+ T cell levels at
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Figure 7 IL-1β and caspase-1 expression in the brains of FIV-infected animals with neurologic defects. A. IL-1β immunoreactivity was
evident in feline monocyte-derived macrophages at 8 and 24 hr following FIV infection while caspase-1 expression was unaffected. B. CD4+ T cell
count in blood of FIV-infected (n = 10) and uninfected animals (n = 6) at weeks 8 and 12 post-infection. C. Neuronal counts per high power field
(400X) from FIV [+] animals versus FIV [−] controls at week 12 D. Immunohistochemical detection of Iba-1, IL-1β and caspase-1 in both striatum
and cortex (CTX) from FIV [−] and FIV [+] animals (original magnification: Iba-1 and IL-1β X200; caspase-1 X600; Nissl stain, X100). Inset ‘i’ shows
an IL-1β immunoreactive microglial nodule. Insets ‘ii’ and ‘iii’ display IL-1β and Iba-1 co-immunolabeling. E. Detection of FIV pol RNA in the cortex
and striatum of FIV [−] (n = 6) and FIV [+] animals (n = 10) at week 12. Performance of FIV [−] (n = 6) and FIV [+] (n = 10) animals in neurobehavioral
tests of gait (F) and memory (G) at week 12 post-infection. “N.D.” indicates that virus was “Not Detected”.
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test. These data highlighted the complexity of the fac-
tors contributing to FIV neuropathogenesis but also
implicated increased CASP1, NLRP3 and IL1B expres-
sion in the cerebral cortex as important components of
neurologic disease.Discussion
The current studies represent the first report of NLRP3
inflammasome-activation and release of IL-1β in response
to HIV-1infection of macrophage cell types in an
envelope-dependent manner. In addition, these studies
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Figure 8 In vivo association of inflammasome-related genes with neurological disease in FIV [+] animals. A. Relative fold change (RFC) in
mRNA expression of inflammasome- related and immune genes in the cortex and striatum of FIV [+] (n = 6) and FIV [−] (n = 10) animals at
12 weeks post-infection. Mean RFC values are reported. Bars indicate standard error. *indicate p-value of <0.05. B. Principal component analysis
(PCA) comparing 49 clinical, neurobehavioral and molecular variables in FIV [−] and FIV [+] animals. PC1 represents the separation of the FIV [−]
and FIV [+] animals while PC2 represents intra-group variance. C. Hierarchical Cluster Analysis of multivariate similarities between variables and
animals. Only variables that significantly contributed to PC1 (infection status) are presented in the heat map.
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http://www.retrovirology.com/content/11/1/35expression in human brains, and the first to be comple-
mented by similar analyses of inflammasome expression
and/or activation in primary human CNS cell types in-
cluding microglia, astrocytes and neurons. The present
clinical, in vitro and in vivo model studies all point to
brain macrophage cell types as the chief cells mediating
inflammasome-associated actions. Importantly, these
observations indicate that inflammasome activation by
HIV-1 and the closely related lentivirus, FIV, occurred
immediately after virus exposure to macrophage cells,
in a caspase-1 dependent manner. Moreover, product-
ive viral replication of cells was not a requirement forinflammasome induction, as evidenced by the capacity
of HIV-1 gp120 to induce IL-1β release from microglia
cells and non-replicating virus exposure to induce release
from THP-1 cells. Finally, increased NLRP3, caspase-1 and
IL-1β expression, particularly within the cerebral cortex
were integral components of FIV-mediated neurovirulence,
evident as cortical neuronal loss and complex neurobehav-
ioral deficits, underscoring the potential importance of
inflammasome activation in lentivirus neuropathogenesis.
Inflammasomes are multi-protein complexes that have
gained attention for their capacity to link the sensing of
infection or injury with subsequent inflammatory caspase
Walsh et al. Retrovirology 2014, 11:35 Page 12 of 18
http://www.retrovirology.com/content/11/1/35activation and ensuing cleavage and release of the inflam-
matory cytokines, IL-1β and IL-18. The NLRP3 inflamma-
some is widely regarded as a general sensor of cellular
injury or insult because the list of its activating stimuli is
broad. The occurrence of specific cell physiological events,
such as the lowering of intracellular K+, point to a shared
activation pathway [47]. Another commonality shared
by many NLRP3 activators (perhaps because it triggers K+
efflux) is the ability to destabilize endosomes following up-
take. Crystalline salts, bacterial toxins and viral particles
have all been reported to activate the NLRP3 inflamma-
some following endocytosis [48-51]. Microglia have also
been reported to sense several disease-associated proteins
through this pathway, including amyloid-β, mutant SOD1
and prion protein (PrP) [52-54].
The increased expression of IL-1β, IL-18 and caspase-1
observed herein among brains from HIV-1 infected per-
sons was highly indicative of inflammasome activation dur-
ing HIV-1 infection, prompting further investigation of this
possibility. Previous studies have implicated inflammasome
activation within the CNS as part of the response to
both acute viral and bacterial infections as well as neu-
rodegenerative disease [11-14]. However, few of these
studies have examined human brains and none to our
knowledge have used isolated primary CNS cells from
humans. Therefore, it was imperative to characterize
inflammasome expression in different CNS cell types at
the outset. Along with microglia that represent the CNS
resident mononuclear phagocytic cell, both neurons and
astrocytes have been reported to express active inflamma-
some complexes under certain circumstances [12,41,55].
While not disproving those observations, a direct com-
parison of the expression of inflammasome-related genes
between different human CNS cell types clearly highlighted
microglia as the specialist innate immune cell most likely to
mediate inflammasome-dependent responses. In addition
to microglia, astrocytes (which outnumber microglia
within the CNS by a 10 fold difference) respond to and
subsequently mediate innate/inflammatory signals in the
brain. Responses by activated astrocytes have been re-
ported to include the expression of IL-1β [39-41]. How-
ever, IL-1β expression in human astrocytes at the protein
level was not apparent in the current studies, even in re-
sponse to strong NFκB activators such as LPS. In addition,
despite detection of caspase-1 transcript in primary astro-
cytes the expression of caspase-1 protein was extremely
low or absent from these cells, in striking difference to
microglia in which caspase-1 was readily detected. The
above observations prompted us to focus on investiga-
tions of HIV-1 dependent activation of the inflamma-
some in microglia.
Microglia are permissive to HIV-1 and productive in-
fection can be established in vitro. However, as observed
in the current studies, the peak production and releaseof virus is a temporally delayed event after IL-1β release.
Thus, IL-1β induction and release were early events fol-
lowing HIV-1 exposure and were largely attenuated once
viral production occurred (Figure 3C). These observa-
tions are consistent with studies showing that HIV-
infected macrophages exhibit relatively few features of
immune activation during infection, such as cytokine re-
lease [56,57]. However, innate immune sensing is ex-
pected to be an immediate response to the presence of a
pathogen and indeed expression of IL-1β within human
microglia occurred after a few hours with maximal IL-1β
release after only 24 hr. This finding was similar to the
innate immune response of plasmacytoid dendritic cells
(pDC) to HIV-1 in which sensing of viral RNA by TLR7
within endosomes mediated a type 1 interferon response
after overnight exposure to virus [19]. The relationship
between HIV-1 and the innate immune response is as-
sumed to contribute to subsequent pathogenesis. This as-
sumption is exemplified by the differences observed in the
transient type 1 interferon response of natural (African)
non-human primate hosts to SIV infection, as compared
to the chronic expression of interferons observed in Asian
macaques in which SIV infection is highly pathogenic
[58]. However, the pathogenic effects of a persistent re-
sponse from some cells may be exacerbated by the lack of
a response to HIV-1 by other innate immune cell types
coupled with the ability of the same cells to transmit sur-
face bound virus to CD4+ T cells in a highly efficient man-
ner [59]. Regarding the release of IL-1β from microglia in
response to HIV-1 or FIV infections and its relationship
to pathogenesis, the multivariate analyses of FIV-infected
animals suggested that elevated expression of caspase-1,
NLRP3 and IL-1β contributed to the development of
brain disease.
In West Nile Virus infection of mice, IL-1β production
was reported to be protective although the response was
mediated by murine neurons, which are infected by this
virus [12]; HIV-1 does not infect neurons. Conversely,
murine models of bacterial meningitis as well as a number
of chronic neurodegenerative diseases including amyo-
trophic lateral sclerosis (ALS) and Alzheimer’s disease
(AD) have linked inflammasome-dependent IL-1β release
to the promotion of disease [11,13,53]. Gene expression
profiling has identified overlap between HIV-1-associated
neurocognitive disorders and other chronic neurodegener-
ative diseases such as Alzheimer’s and multiple sclerosis
[60]. Typical features of HIV-1 infection of the brain are
the occurrence of multinucleated giant cells and micro-
glial nodules; immunohistochemical examination of the
brains of SIV-infected macaques identified an enrichment
of IL-1β immunopositive cells in these lesions [23]. We
observed a similar enrichment in lesions in the brains of
both humans and cats. In addition, it was noted in ma-
caques that the IL-1β immunopositive cells interacting
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themselves SIV-immunopositive [23]. These above obser-
vations lead us to the speculation that infected microglial
nodules, which are repeatedly surveyed by naïve microglia
with subsequent inflammasome activation and IL-1β re-
lease, could be acting as the seed site of a chronic inflam-
matory state that promotes cumulative CNS injury.
The specific inflammasome complex implicated in all of
the aforementioned CNS diseases was the NLRP3 inflam-
masome. Here we report that IL-1β release in response to
HIV-1 exposure is also dependent on NLRP3. This con-
clusion is supported by the ability of high extracellular K+
to inhibit the response, as well as by the attenuation of the
response in a NLRP3 deficient THP-1 cell line (Figure 4C).
An NLRP3-dependent response has recently been re-
ported for monocyte-derived macrophages as well as
THP-1 cells that were exposed to Hepatitis C virus (HCV)
[51]. These events were mediated by the phagocytic up-
take of HCV into endosomes and were independent of
productive infection [50]. These authors also proposed
TLR7 dependent sensing of viral RNA acted as a Signal 1
and induced the expression of IL-1β. Signal 2 was related
to K+ efflux. The events constituting Signal 1 and 2 in re-
sponse to HIV-1 remain to be elucidated. It should be
noted that we could not detect IFNα release from HIV-1
exposed microglia (data not shown), as is reported to
occur in pDCs [19-21] although we have previously re-
ported on the induction of IFN-responsive genes in micro-
glial cultures following HIV-1 exposure [61]. Arguing
against a role for viral RNA and TLR7 in promoting IL-1β
expression in HIV-1 exposed microglia is the observation
that recombinant HIV-1 gp120 was sufficient to induce
IL-1β expression and release from these cells. Soluble
gp120 has been reported to exert toxic effects within the
nervous system [62] and interestingly, treatment of micro-
glial cells with gp120 has been reported to trigger an out-
ward K + current [63]. Although the extent to which the
response to soluble HIV-1 gp120 recapitulates the host re-
sponse to intact live HIV-1 is limited, the induction of IL-
1β expression and the NLRP3 inflammasome in response
to an isolated protein is not without some precedent. For
example, the bacterial protein Td92 was reported to acti-
vate the NLRP3 inflammasome through binding to the
α5β1 integrin receptor [64].
Conclusions
The present studies point to the rapid induction of IL-1β
in conjunction with inflammasome activation within brain
macrophage lineage cells in response to infection by HIV-1
(and FIV). These events were associated with neuroviru-
lence, implying inflammasome activation might represent
a potential therapeutic target. Future studies using pro-
posed inflammasome inhibitors, including anti-IL-1β ther-
apies such as anti-human monoclonal antibodies and IL-1receptor antagonists, which have been used successfully to
treat Cryopyrin-associated syndromes [65], might also be
suitable for treating HIV-1 infection. Similarly, the devel-
opment of new drugs such as Cytokine Release Inhibitory
Drug (CRID)3 [66] and Milk fat globule-EGF 8 (MFGE8)
[67], or repurposing existing drugs, such as glyburide [68]
might hold promise as adjunct treatments for neurotropic
infections such as HIV-1.
Methods
Ethics statement
The use of autopsied brain tissues is part of ongoing re-
search (Pro00002291) approved by the University of
Alberta Human Research Ethics Board (Biomedical).
Written informed consent documents were signed for all
samples collected. The protocols for obtaining post-mortem
brain samples comply with all federal and institutional
guidelines, with special respect for the confidentiality of the
donor’s identity. Human fetal tissues were obtained from 15
to 20 wk aborted fetuses directly from the clinic with the
written informed consent of the patient (Pro00027660)
approved by the University of Alberta Human Research
Ethics Board (Biomedical). All animal experiments were
performed according to the Canadian Council on Animal
Care (http://www.ccac.ca/en) and local animal care and
use committee guidelines. The experiments involving FIV-
infected cats were part of ongoing studies (AUP00000315)
approved by the University of Alberta Animal Care and
Use Committee.
Reagents
Antibodies against human IL-1β, caspase-1 and actin were
from Santa Cruz Biotechnology (Cat #sc-7884, sc-515, sc-
1616). Anti-IL-18 was from MBL (Cat #D043-3). Anti-
MHCII was from Dako (Cat #M0775). Anti-ASC was
from AdipoGen (Cat #AL177). Anti-NLRP3 was from
LSBio (Cat #LS-B4321). Anti-Iba-1 was from Wako (Cat
#019-19741). Anti-canine IL-1β with cross-reactivity to fe-
line IL-1β was from Kingfisher Biotech (Cat #PB0125D).
The caspase inhibitor, YVAD-fmk, and the human IL-1β
ELISA development kit were obtained from R and D
Systems (Cat #FMK005, DY201). HIV-1 p24 antigen
capture assay was obtained from Advanced Bioscience
Laboratories (Cat #5421). Adenosine triphosphate (ATP)
and Phorbol 12-myristate 13-acetate (PMA) were obtained
from Sigma (Cat #A2383 and P8139). HIV-1 gp120 CM en-
velope protein (Cat #2968), AZT (Cat #3485), Efavirenz
(Cat #4624), T20 (Cat #9845) and Maraviroc (Cat #11580)
were obtained through the NIH AIDS Research and Refer-
ence Reagents Program, Division of AIDS, NIAID, NIH.
Cells and viruses
THP-1 cells were cultured in RPMI (10% FBS). To dif-
ferentiate, cells (5×105 cells/well) were treated for 24 hr
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were washed once with PBS and fresh media without
PMA was added to the cells. Cells were allowed to rest
for a further 24 hr without PMA before use in experi-
ments. THP1-defNLRP3 cells (InvitroGen Cat #thp-
dnlp) were treated in the same manner. THP-1 and
THP1-defNLRP3 cells were transfected with 1 μg poly
dA:dT using 2 μl of lipofectamine 2000 (Invitrogen Cat#
52887). Human fetal astrocytes, neurons or microglia
were isolated based on differential culture conditions, as
previously described [32-38,69]. Briefly, fetal brain tis-
sues were dissected, meninges were removed, and a sin-
gle cell suspension was prepared through enzymatic
digestion for 30 min with 0.25% trypsin and 0.2 mg/ml
DNase I, followed by passage through a 70-μm cell
strainer. Cells were washed twice with fresh medium
and plated in T-75 flasks coated with poly-L-ornithine at
6–8 × 107 cells/flask. Cultures were maintained in MEM
supplemented with 10% FBS, 2mM L-glutamine, 1mM
sodium pyruvate, 1 ×MEM nonessential amino acids,
0.1% dextrose, 100 U/ml Penicillin, 100 μg/ml strepto-
mycin, 0.5 μg/ml amphotericin B, and 20 μg/ml gentami-
cin. For neuronal cultures, 25 μM cytosine arabinoside
was added to clear the culture of proliferating cells (astro-
cytes). Astrocyte cultures were passaged once per week for
4–6 weeks until the neurons were eliminated. For micro-
glial cells, mixed cultures were maintained for 2weeks at
which point astrocytes and neurons formed an adherent
cell layer with microglia loosely attached or free float-
ing in the medium. Cultures were gently rocked for
20min to suspend the weakly adhering microglia in
medium, which were then decanted, washed and plated.
Purity of cultures was verified as previously reported by
our group [32-38]. For infections and functional experi-
ments, human microglia were plated onto 16 well glass
chamber slides (70,000 cells/well) and allowed to rest
for 3days prior to treatment.
The HIV-1 R5-dependent strain, HIV-1SF162, was pro-
duced by infecting activated human peripheral blood
mononuclear cells (PBMCs) that were maintained in RPM
(with human IL-1 supplementation) [34]. Day 7 or day 10
culture supernatants containing virus were centrifuged at
low speeds followed by filtration through 0.22 μm filter to
remove cellular debris. Supernatants were further filtered
through a 100K centrifugation in filter to dialyse out small
molecular weight species. The filtered viral stocks were
re-suspended in OptiMEM media and the HIV-1 p24 con-
centration was quantified by ELISA and for experiments
using microglia an inoculum (p24 20 ng/ml) was used to
infect cells.
Production of pseudotyped viruses and infection
Pseudotyped HIV-1 virus stocks were generated by co-
transfection of 293 T cells (8 × 106) with 8 μg of envelope-defective HIV-1 proviral construct HxBruR+/E− and 8 μg
of vesicular stomatitis virus glycoprotein envelope (VSV-
G) or HIV-1 envelope construct pSVIII-92TH014.12 (NIH
AIDS Reagent #3098) using Lipofectamine 2000 (Invitro-
gen) according to manufacturer’s protocol. Forty-eight
hours post-transfection, supernatants were collected, cen-
trifuged at 500 × g for 10 min and filtered through
0.45 μm filters. The supernatants containing pseudotyped
HIV-1 viral particles were quantified by HIV-1 p24 ELISA
and used for infecting THP-1 cells. THP-1 cells (0.5 × 106)
cells were infected overnight with HIV-1 pseudotyped
with either the VSV-G (HxBruR+/E− + VSVG) or the HIV-
1 envelope protein, (HxBruR+/E− +HIV-1Env3098) using an
innoculum of 60ng/ml HIV-1 p24. HIV-1YU-2 stocks, gener-
ated by transfection of 293 T cells with HIV-1YU-2 proviral
DNA, were used as a positive control. Culture supernatants
were collected 24h post-infection and assayed for IL-1β
by ELISA. The HIV-1 envelope construct was obtained
through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: pSVIII-92TH014.12.
Animals
Adult pregnant cats (queens) were housed in the Univer-
sity of Alberta animal care facility and maintained accord-
ing to the Canadian Committee of Animal Care guidelines.
All queens were seronegative for feline retroviruses (FIV,
FeLV). On Day 1 postpartum, animals were intracranially
implanted (right hemisphere) with 200 μl of virus (104
TCID50/mL; FIV-Ch or mock-infected). Animals were
monitored daily over a 12 week period post-infection dur-
ing which time body weight was measured, neurobehavioral
tests were performed, and blood samples were collected.
Animals were euthanized by pentobarbital overdose at 12
weeks. Tissue samples were collected and either snap fro-
zen or fixed in 4% buffered paraformaldehyde to preserve
them for subsequent analysis.
RT-PCR
Total RNA from cells or tissue samples was isolated
using TRIzol reagent (Invitrogen Cat # 15596018) and
the RNeasy purification kit (Qiagen). cDNA was synthe-
sised using superscript II reverse transcriptase (Invitro-
gen Cat # 100007925). Conventional PCR was visualized
by agarose gel stained with Ethidium Bromide. Semi-
quantitative real-time PCR was performed using SYBR
green (BioRad IQ SYBR supermix) detection and the
Delta-Delta CT method. Threshold cycle values for the
gene of interest were normalized to GAPDH and are
represented as the average relative fold change (RFC)
compared with control samples.
Immunohistochemistry
HIV/FIV [−] and HIV/FIV [+] brain tissue samples were
paraformaldehyde-fixed and paraffin-embedded before
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jected to antigen retrieval (boiling in 10 mM sodium
citrate pH6) before immunostaining. Immunoreactivity
was detected using 3,3’-diaminobenzidine tetrachloride
(DAB; brown) and/or 5-bromo-4-chloroindolylphosphate
(BCIP; purple).
Immunofluorescence studies
Cultured human microglia, astrocytes and neurons were
seeded on an 8 well-chamber μ-slide (ibidi, Germany)
and fixed with 4% paraformaldehyde in PBS for 15mi-
nutes and blocked with blocking buffer (Li-cor Biosci-
ences) for 1 h at room temperature. Cells were then
incubated with primary antibodies specific to Iba-1
(1:250, Wako), ASC (1:200, AdipoGen), MAP-2 (1:250,
BD Biosciences) and GFAP (1:800, Dako) overnight at
4°C. Following washes with blocking buffer, cells were
incubated with AlexaFluor secondary antibodies, anti-
rabbit (647 nm, red) and anti-mouse (487, green) (1:100,
Life Technologies). Cell nuclei were visualized by incu-
bating with Hoechst nuclear dye (1:100, ImmunoChem-
istry Technologies) for 15minutes. Images were captured
using an Olympus IX-81 confocal microscope (Quorum
Technologies) using the Volocity Software.
Caspase-1 detection assay
Human microglia were grown on a microtiter 96-well
plate (50,000/well) with a clear bottom and black
walls (Greiner Bio-one, Germany). Cells were mock or
HIV-1SF162 infected following which caspase-1 activity
was assayed using FAM-FLICA™ caspase-1 assay kit
(ImmunoChemistry Technologies Cat#98) according to
manufacturer’s protocol. Briefly, cells were incubated
with FAM-FLICA reagent for 1 h at 37°C and cells were
washed and incubated with media for 30 minutes to dif-
fuse unbound FLICA. Plates were then read by setting
excitation at 488 nm and emission at 530 nm using a
microplate reader (Synergy™ HT, Biotek Instruments,
Inc.). Adherent cells plated in 8 well-chamber slide
were mock or HIV-1SF162 infected. At 24 hr post-infection,
cells were fixed with 4% paraformaldehyde in PBS for
15minutes, following incubation with FAM-FLICA and
visualised as green florescence with Olympus IX-81
confocal microscope (Quorum Technologies) using
Volocity Software.
Cell stimulation\infection
For experiments involving THP-1 or THP1-defNLRP3
cell lines, PMA differentiated cells (5×105 cells/well) were
exposed to HIV-1SF162 (20 ng/mL viral p24) or trans-
fected with poly dA:dT (4 μg/mL). Transfections were
performed using Lipofectamine 2000 reagent (7 μl/mL)
(Invitrogen Cat # 52887). Samples were collected after
3 hr and collected supernatants were centrifuged toremove any cellular debris. IL-1β release was measured
by ELISA.
For long term infection experiments of primary human
microglia, cells (7×104 cells/well) were initially exposed
to HIV-1SF162 (HIV-1 p24, 20 ng/mL) for 24 hr at which
time input virus was removed and wells were washed to
remove free virus (4 × 300 μl PBS) before adding new
media. Cell supernatants were subsequently collected
every 3 days to determine both IL-1β and viral p24 re-
lease. Samples were analyzed by ELISA. For short term
exposure experiments, microglia (7×104 cells/well) were
initially exposed to HIV-1SF162 as described above, for
18 hr before input virus was removed and new media
was added to the wells. Samples were subsequently col-
lected after allowing the cells to incubate with new
media for a further 6 hr. Both cell supernatants for
ELISA and cell lysates for western blot analysis were col-
lected. For time course experiments, samples were taken
at each time point following addition of the virus with-
out further incubation.
For inhibitor treatments (i.e. YVAD-fmk, KCl, mara-
viroc or efavirenz), cells were pre-incubated for 1 hr at
37°C with each reagent prior to addition of infectious
virus. For the viral inhibitor T20, virus was pre-
incubated with T20 for 1 hr at 37°C prior to addition of
virus to cells. In parallel, untreated virus was also pre-
incubated at 37°C.
Behavioral analysis of FIV infected cats
Neurobehavioral parameters in 12 week mock- (n = 6) or
FIV-infected (n = 10), animals were evaluated. The be-
havioural tests employed have been described in detail
previously [70]. Briefly, locomotor ability was deter-
mined by analyzing the inked footprints formed by cats
walking across a suspended plank. Distance between the
right and left paw placement was measured and the vari-
ance in gait width calculated. Spatial memory and cogni-
tive ability was measured using a modified T-maze.
The duration and number of errors to completion of
the maze were recorded. The Object-Memory test was
utilized to measure both spatial and object memory
functions. Animals were required to step over a 6 cm
moveable barrier with their forelimbs to reach a food re-
ward. Their ability to remember the height and position
of the barrier was monitored using reflective markers
placed on the lateral aspects of the animal’s hindlimbs.
Animal performance was recorded on video. The num-
ber of successful attempts were counted and recorded as
a percent of total.
Univariate statistical analyses
Statistical analyses of gene expression and in vitro cellu-
lar responses were performed using the Student t-test
(2-tailed).
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Data for each variable was converted to z-scores to allow
unbiased analysis. Missing data values were imputed
using the standard k-nearest neighbor (k-NN) method-
ology (k = 3) [71] Principal components analysis (PCA)
was performed to investigate multivariate correlation
within the data [72]. PCA is a mathematical procedure,
which enables the correlation between the N observed
variables to be projected onto a smaller set of linearly
uncorrelated latent variables called Principal Components
(PCs). This PCA projection summarizes the predominant
patterns in the multivariate data. The PCs are calculated
such that the first PC describes the direction of maximum
variance in the multivariate data and each subsequent PC
in turn describes the next highest orthogonal (uncorre-
lated) direction variance in the data. A PCA score plot is a
projection of the original data set onto the PC axes, with
each point representing a single animal. Clustering of
points indicates a strong correlation (i.e. similar variable
profile). Variables that contribute significantly to each axis
of the PCA projection can be readily determined using
bootstrap re-sampling [73].
To assess the multivariate similarities of those vari-
ables significantly contributing to the PCA, unsupervised
2-way Agglomerative Hierarchical Cluster Analysis (HCA)
was performed [74]. This algorithm used a multivariate
Euclidean distance metric and Ward’s group linkage to
generate the 2-way hierarchical cluster trees; it clustered
first with respect to animals and then to variables. The re-
sults were displayed as a heatmap with associated cluster
dendrograms; the lower the linkage in the dendrogram,
the more similar the feature.
Additional files
Additional file 1: Figure S1A. Semi-quantitative real-time PCR showing
the relative fold change in expression in THP-1 cells and primary human
microglia or astrocytes. B. IL-1β expression in microglia following
infection with HIV-1SF162. Prior to infection, cells were pre-treated with
buffer control or with AZT (10 μg/mL) or Efavirenz (1 μg/mL). C. IL-1β
release from microglia following infection with HIV-1SF162. Prior to
infection, cells were pre-treated with buffer control or cytochalasin D.
E. IL-1β release from PMA-differentiated THP-1 cells exposed to HIV-1SF162
or HIV-1NL4–3 for 4 hr.
Additional file 2: Figure S2A. NLRP3 mRNA expression in THP1-defNLRP3
cells relative to conventional THP-1 cells with and without PMA
differentiation of cells.
Additional file 3: Figure S3A. CD8+ T cell levels in blood of FIV [−] and
FIV [+] animals at week 8 and week 12 post-infection. B. and C. Performance
of FIV [−] and FIV [+] animals in neurobehavioral tests at week 12
post-infection. D. Mean weights of FIV [+] and FIV [−] animals over 12 weeks.
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of inflammation-related genes in the cortex or striatum of FIV [+] cats
versus FIV [−] controls.
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